Oncology Institute (NASDAQ:TOI) Receives “Buy” Rating from Needham & Company LLC

Oncology Institute (NASDAQ:TOI)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. Needham & Company LLC’s target price indicates a potential upside of 79.86% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oncology Institute currently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

Oncology Institute Trading Down 2.5%

Shares of TOI stock opened at $2.78 on Monday. The company’s fifty day simple moving average is $3.10 and its 200-day simple moving average is $3.42. Oncology Institute has a 52 week low of $0.60 and a 52 week high of $4.88. The company has a market cap of $273.50 million, a PE ratio of -4.34 and a beta of 0.14.

Insider Transactions at Oncology Institute

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $3.77, for a total value of $50,265.41. Following the completion of the sale, the director owned 683,721 shares of the company’s stock, valued at $2,577,628.17. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Oncology Institute

A number of large investors have recently added to or reduced their stakes in TOI. LPL Financial LLC increased its stake in Oncology Institute by 1.5% during the 4th quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock worth $964,000 after buying an additional 3,900 shares during the period. AQR Capital Management LLC boosted its position in Oncology Institute by 9.1% in the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock valued at $171,000 after buying an additional 4,007 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Oncology Institute by 5.5% during the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after acquiring an additional 4,489 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after acquiring an additional 4,545 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Oncology Institute by 19.7% during the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company’s stock worth $112,000 after acquiring an additional 5,181 shares during the last quarter. 36.86% of the stock is owned by institutional investors and hedge funds.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.